Clinical trial
Hybrid PET/CT in Cancer Patients
NCT00396916 · Rambam Health Care Campus, Other · Completed
Key facts
| NCT number | NCT00396916 |
|---|---|
| Title | Hybrid PET/CT in Cancer Patients |
| Official title | The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin |
| Lead sponsor | Rambam Health Care Campus, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Device |
| Interventions | PET/CT imaging |
| Enrollment | 45 |
| Start date | Dec 1, 2004 |
| First posted | Nov 8, 2006 |
| Last update posted | Apr 11, 2007 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: